DURECT Corporation Invites You to Join its Fourth Quarter and Year-End 2004 Conference Call on the Web

Download PDF:

CUPERTINO, Calif., Jan. 20 /PRNewswire-FirstCall/ — In conjunction with
DURECT Corporation’s (Nasdaq: DRRX) fourth quarter and year-end 2004 financial
results press release, you are invited to listen to its conference call that
will be broadcast live over the Internet on Thursday, February 10, 2005 at
4:30 p.m. EST with Jim Brown, President and Chief Executive Officer,
Tom Schreck, Chief Financial Officer and Felix Theeuwes, Chairman and Chief
Scientific Officer.

(Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO )

What: DURECT Corporation’s Fourth Quarter and Year-End 2004 Earnings
Conference Call

When: Thursday, February 10th, 2005, 4:30 p.m. EST (1:30 p.m. PST)

Where: www.www.durect.com and click ‘Investor Relations’
Live over the Internet — Simply log on to the Web at the address
listed above.

If you are unable to participate during the live webcast, the call will be
archived on DURECT’s website under Audio Archive in the “Investor Relations”
section.

About DURECT Corporation

DURECT Corporation is an emerging specialty pharmaceuticals systems
company focused on the development of pharmaceutical systems based on its
proprietary drug delivery platform technologies that treat chronic
debilitating diseases and enable biotechnology products. These platform
technologies include the SABER(TM) Delivery System (a patented and versatile
depot injectable useful for protein and small molecule delivery), the
ORADUR(TM) sustained release oral gel-cap technology (an oral sustained
release technology with several potential abuse deterrent properties), the
DURIN(TM) Biodegradable Implant (drug-loaded implant system) and the
MICRODUR(TM) Biodegradable Microparticulates (microspheres injectable system).
DURECT also collaborates with pharmaceutical companies to develop and
commercialize proprietary and enhanced pharmaceutical products based on its
technologies. DURECT has five disclosed on-going development programs of which
three are in collaboration with pharmaceutical partners. Additional
information about DURECT is available at www.www.durect.com.

NOTE: SABER(TM), ORADUR(TM), DURIN(TM) and MICRODUR(TM) are trademarks of
DURECT Corporation. Other referenced trademarks belong to their respective
owners.

SOURCE DURECT Corporation
01/20/2005

CONTACT:
Schond L. Greenway
Executive Director, Investor Relations and
Strategic Planning, of DURECT Corporation,
408-777-1417

/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, +1-888-776-6555 or +1-212-782-2840/
/Web site: http://www.www.durect.com/
01/20/2005 07:30 EST http://www.prnewswire.com

Scroll to Top